SOUTH SAN FRANCISCO, Calif., March 1 (UPI) -- Sunesis said Thursday it filed an investigational new drug application with the U.S. Food and Drug Administration for its anti-cancer agent SNS-314.
The compound inhibits Aurora kinases, which are enzymes involved in cancer cell growth and division.
"With SNS-314, we have observed robust, dose-dependent activity under multiple dosing schedules, which should provide greater dosing flexibility in the clinic than competitor candidates," said Daniel Adelman, Sunesis' senior vice president of research and development.
"In our first phase 1 study, we plan to dose SNS-314 intravenously on a weekly basis," Adelman added.
Daniel Swisher, Sunesis' chief executive officer and president, said the company anticipates initiating a clinical trial involving patients with advanced solid tumors in the second quarter.
